DJIA 17,745.98 -5.41 -0.03%
NASDAQ 5,128.79 17.05 0.33%
S&P 500 2,108.63 0.06 0.00%
market minute promo

RECEPTOS INC (NASDAQ: RCPT)

227.48 -0.16 (-0.07%)

Quote as of

Extended Hours: $227.86 $0.38 (0.17%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

RCPT $227.48 -0.07%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $227.65
Previous Close $227.64
Daily Range $227.20 - $228.49
52-Week Range $40.00 - $230.87
Market Cap $7.2B
P/E Ratio -46.36
Dividend (Yield) $0.00 (0.0%)
Volume 919,714
Average Daily Volume 1,458,952
Current FY EPS -$5.60

Sector

Industry

RECEPTOS INC (RCPT) Description

RECEPTOS INC Website: http://www.receptos.com/

News & Commentary

Celgene Rolling Along (but You Already Knew That)

After pre-releasing revenue and sales numbers last week, investors got more details on the biotech's second-quarter earnings.

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up

Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog

Celgene's Q2 Earnings Call: Highlights & Analyst Commentary

Evercore ISI's Schoenebaum Breaks Down Celgene-Receptos Merger

5 Reasons Celgene Corporation Is a Buy

Celgene has been a monster stock for investors, and this Fool thinks the future continues to look bright. Here are five reasons Celgene is a buy today.

A Few Key Points I Am Watching For From Gilead Sciences

Celgene Buys Receptos. Is Arena Pharmaceuticals Next?

Both biotechs have S1P1 receptor drugs, but they're not created equal.

Piper Jaffray Still Overweight Biogen But Notes It's Least-Preferred Play; Hikes Celgene Target

The Value Of The Receptos Acquisition For Celgene

See More RCPT News...